Protective efficacy of hepatitis B vaccines in neonates

Journal of Medical Virology

Volumn 44, Issue 2, 1994, Pages 144-151

  André, Francis E ^a   Zuckerman, Arie J ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

dose; immunisation; schedule

Indexed keywords

HEPATITIS B VACCINE; IMMUNOGLOBULIN;

ARTICLE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; NEWBORN; NEWBORN CARE; UNITED KINGDOM;

DISEASE TRANSMISSION, VERTICAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMAN; IMMUNIZATION SCHEDULE; IMMUNOGLOBULINS; INFANT; INFANT, NEWBORN; PREGNANCY;

HEPATITIS B VIRUS;

EID: 0028126666     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.1890440206     Document Type: Review

References (59)

1. Progress in the control of viral hepatitis: Memorandum from a WHO meeting
2. Efficacy of a low‐dose plasma‐based vaccine in the prevention of HBV carriage in children
3. Hepatitis B vaccine set for introduction into national immunization programmes
4. Immunogenicity of a reduced dose of yeast‐derived hepatitis B vaccine and its efficacy in the prevention of perinatal transmission of HBV infection
5. Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high‐risk neonates
6. Long term efficacy of hepatitis B immunoprophylaxis in neonates at high risk: Using different vaccine and schedule
7. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults
8. Thee e antigen and vertical transmission of hepatitis B surface antigen
9. Prevention of perinatally transmitted hepatitis B immune globulin and hepatitis B vaccine
10. A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination
11. Virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP)
12. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigencarrier mothers
13. The Gambia hepatitis intervention study: Follow‐up of a cohort of children vaccinated against hepatitis B
14. The Montreal hepatitis B virus immunization study group (1988): Combined active‐passive immunization against the hepatitis B virus of 132 newborns of chronic carrier mothers: Long term results
15. Immunogenicity of 20 μg of recombinant DNA hepatitis B vaccine in healthy neonates: A comparison of three different vaccination schedules
16. Occupational exposure to hepatitis B virus in hospital personnel: Infection or immunization?
17. The assessment of immunity against hepatitis B after vaccination
18. Perinatal transmission of hepatitis B virus in high incidence countries
19. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA
20. The efficacy of additional revaccination with hepatitis B when anti‐HBs became negative on long follow‐up
21. Low‐dose hepatitis B vaccine
22. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen‐positive‐hepatitis B surface antigen carrier mothers
23. Immunogenicity and protective efficacy on low‐dose hepatitis B vaccine in new‐borns of HBsAg‐carrier mothers
24. Efficacy of the national hepatitis B vaccination program in the Republic of China: Preliminary observations from Taoyuan area
25. Long‐term follow‐up of recombinant and plasma‐derived hepatitis B vaccines in infants born to HBsAg‐carrier mothers
26. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen‐positive carrier mothers
27. Hepatitis B: Evolving epidemiology and implications for control
28. Hepatitis B infection and primary liver cancer
29. Control of hepatitis B by immunization: Global perspectives
30. Global control of hepatitis B through vaccination: Role of hepatitis B vaccine in the expanded programme on immunization
31. Human hepatitis B vaccine from recombinant yeast
32. Prevention of vertical transmission of HBV by administration of hepatitis B vaccine combined with HBIg and long‐term follow‐up of HBsAb titer
33. Development of hepatitis B vaccine from transformed yeast cells
34. Perinatal transmission of hepatitis B virus in Thailand
35. Hepatitis B immunization in high risk neonates born from HBsAg and HBeAg positive mothers: Comparison of standard and low dose regimens
36. Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: Comparison between plasma derived and recombinant DNA vaccine
37. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B E antigenpositive mothers
38. Randomized, single‐blind comparison of the immunogenicity and reactogenicity of 20 μg and 10 μg doses of hepatitis B vaccine in adolescents
39. Persistence of antibodies after immunization with a recombinant yeast‐derived hepatitis B vaccine following two different schedules
40. Vertical transmission of hepatitis B antigen in Taiwan
41. Hepatitis B immune globulin and yeast‐recombinant hepatitis B vaccine in prevention of perinatal HBV infection in the USA
42. Prospects for control of hepatitis B virus infection: Implications of childhood vaccination and long‐term protection
43. Sociodemographic aspects of the epidemiology of hepatitis B
44. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax‐B): A final report
45. A comparison between the efficacy of passive‐active and active immunization for prevention of perinatal transmission of hepatitis B virus
46. Two‐year study of passive‐active immunization for prevention of hepatitis B infection in newborns
47. Prevention of hepatitis B infection in infants born to hepatitis B carrier mothers: Low dosage vaccination
48. Chronicity rate of hepatitis B virus infection in the families of 60 hepatitis B surface antigen positive chronic carrier children: Role of horizontal transmission
49. Protective efficacy of a recombinant DNA yeast‐derived hepatitis B vaccine (Smith Kline‐RIT) in neonates of HBeAg positive mothers—a multicenter study from Thailand.
50. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: Final report on a West Midlands pilot study
51. Prevention of perinatal transmission of hepatitis B virus (HBV): A comparison of two prophylactic schedules
52. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis‐B vaccine and hepatitis‐B immunoglobulin
53. Expanded Programme on Immunization—global advisory group—Part I
54. Efficacy of the national hepatitis B vaccination program in the Republic of China: Preliminary observations of high risk infants from Taipei municipal women and children hospital
55. United States China Cooperative Study group on hepatitis B